So I emailed CoagSense just to get their take on my findings and here is what they said ;
Systems will rarely match exactly but should correlate. There will be a natural bias that exists between two systems but as long as that bias falls within the WHO and ISO Guidelines for what is considered an acceptable bias there should not be a patient management issue. The values you presented would fall within the acceptable bias range. The difference in technology, thromboplastin and ISI plays a role in contributing towards an inherent bias, and as long as a patient is managed with one system, that is fine. Below are the ISO guidelines for acceptable bias.
. In the INR range below 2.0, 90% of the allowable differences between results from the POC system and reference system shall be ±0.5.
. In the INR range of 2.0 to 4.5, 90% of the allowable differences between results from the POC system and reference system shall be ±30%.
. In the INR range of 4.6 to 6.0, no performance criteria are listed for INR values.
WHO Technical Report Series 889, WHO Expert Committee on Biological Standardization, Forty-eighth report. Section 6.1.1 The Calibration procedure, Calibration of a secondary standard, Blood Samples.Section 7 The use of calibrated thromboplastins in clinical practice.
(ISO/DIS 17593) ISO Draft of 2004, titled "Clinical Laboratory Testing and In Vitro Diagnostic Test Systems-In Vitro Monitoring Systems for Anticoagulant Therapy Self Testing".
The Roche unit tends to run a bit higher. In fact, more recently they have had high INR issues which have resulted in a recall
https://www.fda.gov/medical-devices...t-test-strips-due-inaccurate-inr-test-results
We are still noticing that the Roche system is running higher even with post recall lots of strips.
Again, we recommend only managing your therapy with the Coag-Sense system.